Stay updated on TG4010, Nivolumab & Chemotherapy in NSCLC Clinical Trial
Sign up to get notified when there's something new on the TG4010, Nivolumab & Chemotherapy in NSCLC Clinical Trial page.

Latest updates to the TG4010, Nivolumab & Chemotherapy in NSCLC Clinical Trial page
- CheckyesterdayChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed. There is no impact on the study page's content or how users interact with it.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedAdded a new Locations section listing North Carolina and Tennessee for trial sites. Removed the separate North Carolina Locations and Tennessee Locations sections.SummaryDifference0.3%

- Check51 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2 on the page, indicating a minor site update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check58 days agoChange DetectedThe notice about government funding and NIH operating status has been removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check72 days agoChange DetectedThe study page content remains substantively unchanged between the screenshots; only cosmetic formatting differences are present and no edits to eligibility criteria, interventions, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check101 days agoChange DetectedNew operating-status notice and version update to v3.2.0 are now present, replacing the previous v3.1.0; this adds important information about potential funding-related service limitations and where to check for status.SummaryDifference4%

Stay in the know with updates to TG4010, Nivolumab & Chemotherapy in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TG4010, Nivolumab & Chemotherapy in NSCLC Clinical Trial page.